OssDsign’s Catalyst nanosynthetic bone graft has been used to treat 2,000 U.S. patients to date, up from 1,000 patients treated in May and 500 patients in January.
OssDsign Catalyst is designed to stimulate the formation of healthy bone tissue in spinal fusion surgeries. The graft is composed of a proprietary nanocrystalline structure which is resorbed and replaced by new and healthy bone tissue.
Catalyst was launched in the U.S. in 2021. The market clearance in the U.S. is based on preclinical results that surpass what is typically seen with other synthetic bone grafts in the most demanding preclinical model for spinal fusion – the Boden model. OssDsign continues to accelerate a robust program of gathering clinical evidence anchored by PROPEL, a U.S.-based multi-center prospective spinal fusion registry and TOP FUSION, in which patient enrolment was completed in April 2022.
OssDsign’s Catalyst nanosynthetic bone graft has been used to treat 2,000 U.S. patients to date, up from 1,000 patients treated in May and 500 patients in January.
OssDsign Catalyst is designed to stimulate the formation of healthy bone tissue in spinal fusion surgeries. The graft is composed of a proprietary nanocrystalline structure...
OssDsign’s Catalyst nanosynthetic bone graft has been used to treat 2,000 U.S. patients to date, up from 1,000 patients treated in May and 500 patients in January.
OssDsign Catalyst is designed to stimulate the formation of healthy bone tissue in spinal fusion surgeries. The graft is composed of a proprietary nanocrystalline structure which is resorbed and replaced by new and healthy bone tissue.
Catalyst was launched in the U.S. in 2021. The market clearance in the U.S. is based on preclinical results that surpass what is typically seen with other synthetic bone grafts in the most demanding preclinical model for spinal fusion – the Boden model. OssDsign continues to accelerate a robust program of gathering clinical evidence anchored by PROPEL, a U.S.-based multi-center prospective spinal fusion registry and TOP FUSION, in which patient enrolment was completed in April 2022.
Copy to clipboard 
